港股異動 | 諾誠健華-B(9969.HK)大漲超13%破頂 市值超330億港元
格隆匯2月16日丨諾誠健華-B(9969.HK)大幅拉昇至13.59%,高見22.65港元再創歷史新高價,總市值超330億港元。日前諾誠健華-B已經完成配售2.1億股,當中高瓴資本認購1.92億股、維梧資本認購1,889.5萬股。預計所得款項淨額約30.41億港元,將用於在國內和國際地區擴大和加速正在進行和計劃進行的臨牀試驗。另外,奧布替尼聯合治療臨牀試驗申請獲批,諾誠健華董事長兼首席執行官崔霽松表示,目前奧布替尼正在中國及美國進行多中心、多適應症的臨牀試驗。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.